NFKB1 and diabetes mellitus: Oligonol inhibited NF-κB activation under different pathological conditions, including diabetes-induced kidney damage [15], diabetes, CCL4-induced liver injury [16,17], and dextran sulfate sodium-induced colitis [18] in vivo.